One drug at a time: could a simpler blood thinner strategy cut bleeding risk after stents?

NCT ID NCT05955365

Recruiting now Disease control Sponsor: Insel Gruppe AG, University Hospital Bern Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new approach for people with atrial fibrillation who have just received a coronary stent. Instead of taking multiple blood thinners together for months, the experimental group takes only one antiplatelet drug for the first month, then switches to a single anticoagulant. The goal is to see if this simpler routine reduces bleeding complications while still preventing heart attacks, strokes, and stent blockages. About 3,000 participants will be compared to those receiving the standard combination therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: P2Y12 inhibitor (antiplatelet drug) followed by a direct-acting oral anticoagulant (DOAC)
What this could lead to: If this works, it could offer a simpler, safer blood-thinning routine for people with atrial fibrillation who have just had a coronary stent, lowering their risk of serious bleeding without raising the chance of heart attack or stroke.
What could go wrong: This is a large Phase 4 trial, but the strategy is still experimental. It may not protect against stent clotting or stroke as well as the current triple-drug approach, and individual responses to the drugs can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION (AF) ORAL ANTICOAGULATION P2Y12 INHIBITOR PERCUTANEOUS CORONARY INTERVENTION (PCI)

Contacts and locations

Locations

CHU Nîmes
NOT_YET_RECRUITING

Nîmes, 30029, France
Cardiocentro Ticino Institute
RECRUITING

Lugano, Canton Ticino, 6900, Switzerland
Hartcentrum Hasselt
NOT_YET_RECRUITING

Hasselt, 3500, Belgium
Hospital Universitario Marques de Valdecilla
NOT_YET_RECRUITING

Santander, 39008, Spain
Hôpitaux Universitaires de Genève
RECRUITING

Geneva, 1211, Switzerland
IRCCS Humanitas
NOT_YET_RECRUITING

Milan, Rozzano, 20089, Italy
Imperial College London
NOT_YET_RECRUITING

London, SW7 2AZ, United Kingdom
Inselspital, Bern University Hospital, Department of Cardiology
RECRUITING

Bern, 3010, Switzerland
Klinikum Friedrichshafen
NOT_YET_RECRUITING

Friedrichshafen, 88048, Germany
Ospedale Ferrarotto
NOT_YET_RECRUITING

Catania, Catania CT, 95124, Italy
UMC public
NOT_YET_RECRUITING

Amsterdam, 1081, Netherlands
University Hospital Zürich
RECRUITING

Zurich, 8091, Switzerland
Universitätsklinikum Frankfurt/Main
NOT_YET_RECRUITING

Frankfurt am Main, 60590, Germany
Universitätsspital Basel
RECRUITING

Basel, 4031, Switzerland
Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu
NOT_YET_RECRUITING

Poznan, 61-701, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.